Physician profile
Michael Roh
NPI 1548242712
$22,120.41
in general payments reported to CMS, 2019-2025
12 companies · $1,799 in 2025
The $1,799 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $2,245 · 2021: $2,606 · 2022: $2,015 · 2023: $362 · 2024: $57.52 · 2025: $1,799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,174 · Travel and Lodging: $1,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,173.77 |
| Travel and Lodging | $1,044.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $9,298.19 | 2019-2021 | |
| Medtronic USA, INC. | $7,225.07 | 2019 | |
| Medtronic, INC. | $5,135.87 | 2021-2025 | Mazor X System, Adaptix Interbody System With Titan Nanolock Surface Technology, Unid_pass |
| Vertex Pharmaceuticals Incorporated | $156.14 | 2025 | |
| Nuvasive, INC. | $56.40 | 2020-2022 | |
| Si-Bone, INC. | $55.62 | 2025 | |
| Djo, LLC | $47.55 | 2020 | |
| Orthofix Medical, INC. | $37.31 | 2019 | |
| Genentech USA, INC. | $33.79 | 2025 | Vabysmo |
| Mallinckrodt Hospital Products INC. | $32.51 | 2021 | |
| Depuy Synthes Sales INC. | $22.86 | 2021 | |
| Integra Lifesciences Corporation | $19.10 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Roh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.